BOS
GSK icon

Bingham Osborn & Scarborough’s GSK GSK Stock Holding History

Bingham Osborn & Scarborough’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,762
Closed -$311K – 123
2017
Q2 		$311K Buy
+5,762
New +$307K 0.03% 95

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bingham Osborn & Scarborough's GSK Position: Q3 2017 in Review

Bingham Osborn & Scarborough sold out of GSK (GSK) in Q3 2017, closing a stake of 5,762 shares — an estimated $311K sold.

Bingham Osborn & Scarborough first reported a position in GSK in Q2 2017 and held it in 1 quarter. The position peaked at $311K in Q2 2017. 741 funds tracked by Wall St. Rank hold GSK as of Q3 2017.

  • Bingham Osborn & Scarborough reported no remaining GSK position as of Q3 2017 after selling out during the quarter.
  • Bingham Osborn & Scarborough sold 5,762 GSK shares in Q3 2017, an estimated $311K.
  • Bingham Osborn & Scarborough first reported a position in GSK in Q2 2017 and held it in 1 quarter.
  • Bingham Osborn & Scarborough's GSK position peaked at $311K in Q2 2017.
  • 741 funds tracked by Wall St. Rank held GSK as of Q3 2017.

Based on Bingham Osborn & Scarborough's 13F filing for Q3 2017, filed 6 Nov 2017.